Aralik 2021
Inflamatuvar barsak hastalarinda vedolizumab deneyimi: Tek merkez verileri
Vedolizumab experience in patients with inflammatory bowel disease: Single center data
- Ana Sayfa
- Sayılar
- Aralik 2021
- Inflamatuvar barsak hastalarinda vedolizumab deneyimi: Tek merkez verileri...
Özet
Giris ve Amaç: Vedolizumab, orta ve agir aktiviteli inflamatuvar barsak hastaliklarinin tedavisinde kullanilan ?4?7 integrindir. Tümör nekroz faktör antagonisti ilaçlar ile tedavi basarisi saglanamamis inflamatuvar barsak hastalarinda tercih edilmektedir. Çalismamizda tümör nekroz faktör antagonistine cevapsiz, komplike hasta gruplarinda tek merkez verileriyle vedolizumab tedavisinin 12. aydaki etkinligini ve güvenirligini arastirdik. Gereç ve Yöntem: Ocak 2019- Eylül 2020 tarihleri arasinda Haydarpasa Numune Egitim ve Arastirma Hastanesi Gastroenteroloji Klinigine basvuran 6 aydan uzun vedolizumab tedavisi almis tümör nekroz faktör antagonisti deneyimli hastalar çalismaya dahil edilmistir. Vedolizumab tedavisi öncesi ve 12. ayda endoskopik remisyon kaydedildimis- tir. Bulgular: Tüm hastalarin 17’si (%48.5) kadindi. Yas ortalamasi 43 ± 13’tü (22-76). Bu hastalardan 23’ü Crohn hastasi ve 12’si ülseratif kolit hastasiydi. Crohn hastalarinin 15’inde (%65.2) endoskopik remisyon saglanirken, 8 hasta (%34.78) cevapsiz kabul edildi. Ülseratif kolitte ise endoskopik remisyon ve cevapsiz hasta sayisi esitti (n = 6, %50). Sonuç: Çalismamizda, tümör nekroz faktör antagonisti deneyimli hastalarda, özellikle Crohn hastalari olmak üzere inflamatuvar barsak hastalarinda vedolizumab kullaniminin etkin ve güvenilir oldugu gözlemlenmistir.
Abstract
Background and Aims: Vedolizumab is an ?4?7 integrin used in the treatment of moderate-to-severe inflammatory bowel disease. It is preferred in patients with tumor necrosis factor antagonist experience. In our study, we evaluated the efficiency and safety of vedolizumab treatment at 12 months in complicated groups who were unresponsive to tumor necrosis factor antagonist treatment. Materials and Method: Patients admitted to the Haydarpasa Numune Training and Research Hospital Gastroenterology Clinic between January 2019 and September 2020 were included in the study. The patients had been receiving vedolizumab treatment for more than 6 months. Seventeen (48.5%) patients were female. Results: Endoscopic remission was achieved in 15 (65.2%) patients with Crohn’s disease, whereas 8 (34.78%) patients were considered unresponsive. Endoscopic remission was recorded before vedolizumab treatment and after 12 months. The mean age was 43 ± 13 (22 - 76) years. A total of 23 patients had Crohn’s disease and 12 patients had ulcerative colitis. In ulcerative colitis, the number of endoscopic remission and unresponsive patients were equal (n = 6.50%). Conclusion: In our study, it was observed that the use of vedolizumab in patients with tumor necrosis factor antagonist experience was effective and safe.
